Tenax Therapeutics pauses LEVEL-2 enrollment
The company temporarily paused enrollment to amend inclusion criteria and seek FDA Type C feedback after Phase 3 analyses showed benefit in sicker PH-HFpEF patients.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.